ArticleLeukemia2026

Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

Samuli Eldfors et al.PubMed ↗Publisher ↗

No numbers read from the abstract.